Radiation Dose in Radiotherapy from Prescription to Delivery

Total Page:16

File Type:pdf, Size:1020Kb

Radiation Dose in Radiotherapy from Prescription to Delivery IAEA-TECDOC-896 XA9642841 Radiation dose in radiotherapy from prescription to delivery INTERNATIONAL ATOMIC ENERGY AGENCY The originating Section of this publication in the IAEA was: Dosimetry Section International Atomic Energy Agency Wagramerstrasse 5 P.O. Box 100 A-1400 Vienna, Austria RADIATION DOSE IN RADIOTHERAPY FROM PRESCRIPTION TO DELIVERY IAEA, VIENNA, 1996 IAEA-TECDOC-896 ISSN 1011-4289 © IAEA, 1996 Printed by the IAEA in Austria August 1996 The IAEA does not normally maintain stocks of reports in this series. However, microfiche copies of these reports can be obtained from INIS Clearinghouse International Atomic Energy Agency Wagramerstrasse 5 P.O. Box 100 A-1400 Vienna, Austria Orders should be accompanied by prepayment of Austrian Schillings 100, in the form of a cheque or in the form of IAEA microfiche service coupons which may be ordered separately from the INIS Clearinghouse. FOREWORD Cancer incidence is increasing in developed as well as in developing countries. However, since in some advanced countries the cure rate is increasing faster than the cancer incidence rate, the cancer mortality rate is no longer increasing in such countries. The increased cure rate can be attributed to early diagnosis and improved therapy. On the other hand, until recently, in some parts of the world - particularly in developing countries - cancer control and therapy programmes have had relatively low priority. The reason is the great need to control communicable diseases. Today a rapidly increasing number of these diseases are under control. Thus, cancer may be expected to become a prominent problem and this will result in public pressure for higher priorities on cancer care. The creation of adequate treatment facilities and the training of the necessary personnel will take time, in some cases 10 to 15 years. In some relatively advanced developing countries radiation therapy is applied in about 50% of all detected cancer cases. Approximately half of these treatments have curative intent. Surgery and radiotherapy applied individually or combined result in the cure of about 40% of all patients. The application of chemotherapy alone has curative effects only on a small percentage of the cancer patients. Moreover, palliative radiotherapy is often excellent in providing prolonged life and increased life quality for patients with incurable cancer. It is encouraging to note that the results achieved by radiation therapy show continuous improvement. This can be traced back to a number of developments: increased knowledge regarding tumour and normal tissue response to radiation, early diagnosis with improved tumour localisation, improved dosimetry and dose planning. The introduction of modern equipment (CT-scanners, “Co-units, linear accelerators, computerised treatment planning systems, etc.) has been crucial in these developments and makes possible a more accurate target delineation, better treatment planning resulting in irradiation of the Planning Target Volume (PTV) with a highly uniform dose and, simultaneously, a reduction in dose to healthy tissues outside the PTV. Experience shows that high quality radiotherapy can only be achieved if it is conducted by a skilled team working closely together with good communication between various categories of staff. The team must consist of radiation oncologists, radiation physicists and radiographers. It is also shown that dose prescribed and dose delivered have to agree within +/- 5 % in the PTV to achieve a controlled cure rate without excessive complications to normal tissue. Due to the increasing demands for high accuracy in dose delivery, one of the goals of the seminar was to deal with all the different steps in treatment procedure from the decision of treatment strategy to the quality assurance of the treatments. In some advanced developing countries - especially in Latin America - the trend now is to move from “Co-units to linear accelerators. Absolute doses as well as dose distributions from the latter type of therapy machines vary and can easily be altered through service actions or faulty parts. Therefore, seminars and training courses covering all aspects of quality control in radiotherapy and dosimetry are of great importance and should be held regionally or nationally on a regular basis. EDITORIAL NOTE In preparing this publication for press, staff of the IAEA have made up the pages from the original manuscripts as submitted by the authors. The views expressed do not necessarily reflect those of the governments of the nominating Member States or of the nominating organizations. Throughout the text names of Member States are retained as they were when the text was compiled. The use of particular designations of countries or territories does not imply any judgement by the publisher, the IAEA, as to the legal status of such countries or territories, of their authorities and institutions or of the delimitation of their boundaries. The mention of names of specific companies or products (whether or not indicated as registered) does not imply any intention to infringe proprietary rights, nor should it be construed as an endorsement or recommendation on the part of the IAEA. The authors are responsible for having obtained the necessary permission for the IAEA to reproduce, translate or use material from sources already protected by copyrights. CONTENTS L ACCURACY REQUIREMENTS IN RADIOTHERAPY Tumor and normal tissue responses to fractionated non-uniform dose delivery ............... 9 P. Kallman, A. Agren, A. Brahme Converting dose distributions into tumour control probability ..............................................27 A.E. Nahum Definition of treatment geometry in radiation therapy .......................................................... 41 P. Aaltonen Dosimetric precision requirements and quantities for characterizing the response of tumors and normal tissues ..................................................................................................... 49 A. Brahme IL EQUIPMENT REQUIREMENTS Lessons learned from accidents in radiotherapy .......................................................................69 P. Ortiz-Lopez, J. Novotny , J. Haywood Review of WHO/PAHO/IAEA recommendations concerning radiotherapy facilities . 83 G.P. Hanson Alternative designs for megavoltage machines for cancer treatment in developing countries ...................................................................................................................................... 93 C. Bonds, H. Svensson, G.P. Hanson Simulation and radiation treatment in external radiotherapy .............................................. 101 E. Singer Analysis of variations in the dose delivered in radiation therapy ....................................107 D. B. Feld m(a). INTERCOMPARISON The role of SSDL-Helsinki for dosimetry and quality audit in radiotherapy ..................113 P. Aaltonen SSDL Argentina: Dosimetric intercomparison programme for cobalt 60 therapy units .............................................................................................................................123 M. Saravi, S. Papadopulos, H. Mugliaroli A program on quality assurance and dose calibration for radiation therapy units in Venezuela ..................................................................................................................................135 M.C. de Padilla, L. Carrizales, J. Diaz, F. Gutt, A. Cozman 111(b). DOSIMETRY PROCEDURES Radiation dosimetry with plane-parallel ionization chambers: An International (IAEA) Code of Practice [Invited Paper] ...............................................143 P. Andreo, P.R. Almond, O. Mattsson, A.E. Nahum, M. Roos An algorithm to include the bremsstrahlung component in the determination of the absorbed dose in electron beams .........................................................................................159 S.C. Klevenhagen Clinical dosimetry with plastic scintillators - almost energy independent, direct absorbed dose reading with high resolution .....................................................................165 U. Quest, D. Fluhs, H. Kolanoski Absorbed dose beam quality factors for cylindrical ion chambers: Experimental determination at 6 and 15 MV photon be ams ................................................................ 171 C. Cqporali, A.S. Guerra, R.F. Leatano, M. Pimpinella Displacement correction factor versus effective point of measurement in depth dose curve measurements at 60Co gamma rays ................................................................179 A. Bruna, G.R. Velez, M. Brunetto An analysis of some aspects of the attenuation-scatter functions in brachytherapy dosimetry ............................................................................................................................... 185 S.C. Klevenhagen Standardization of iridium-192 coiled source in terms of air kerma output ...................... 199 A. Shanta, K. Unnikrishntm, U.B. Tripathi, A. Kcmnan, P.S. Iyer Calibration of 192 Ir high dose rate brachytherapy sources ................................................... 203 M.H. Marechal, C.E. de Almeida, C.H. Sibata Quality control of Ir-192, Cs-137 and Ra-226 sources for use in brachytherapy .......... 207 C.H. Oyarzun Cortes, AM. PalmaD., H. Pefialoza C., M. Tomicic IV. QUALITY ASSURANCE NETWORK IN RADIOTHERAPY Quality Assurance Network: the European pilot study ........................................................ 213 J Chavaudra, A. Dutreix, S Derreumaux, A. Brider, E. van der Schueren
Recommended publications
  • Chapter 5: Treatment Machines for External Beam Radiotherapy
    Chapter 5: Treatment Machines for External Beam Radiotherapy Set of 126 slides based on the chapter authored by E.B. Podgorsak of the IAEA publication: Radiation Oncology Physics: A Handbook for Teachers and Students Objective: To familiarize the student with the basic principles of equipment used for external beam radiotherapy. Slide set prepared in 2006 by E.B. Podgorsak (Montreal, McGill University) Comments to S. Vatnitsky: [email protected] IAEA International Atomic Energy Agency CHAPTER 5. TABLE OF CONTENTS 5.1. Introduction 5.2. X-ray beams and x-ray units 5.3. Gamma ray beams and gamma ray units 5.4. Particle accelerators 5.5. Linacs 5.6. Radiotherapy with protons, neutrons, and heavy ions 5.7. Shielding considerations 5.8. Cobalt-60 teletherapy units versus linacs 5.9. Simulators and computed tomography simulators 5.10. Training requirements IAEA Radiation Oncology Physics: A Handbook for Teachers and Students - 5.1 Slide 1 5.1 INTRODUCTION The study and use of ionizing radiation in medicine started with three important discoveries: • X rays by Wilhelm Roentgen in 1895. • Natural radioactivity by Henri Becquerel in 1896. • Radium-226 by Pierre and Marie Curie in 1898. IAEA Radiation Oncology Physics: A Handbook for Teachers and Students - 5.1 Slide 1 5.1 INTRODUCTION Immediately upon the discovery of x rays and natural radioactivity, ionizing radiation has played an important role in: • Atomic and nuclear physics from the basic physics point of view. • In medicine providing an impetus for development of radiology and radiotherapy as medical specialties and medical physics as a specialty of physics.
    [Show full text]
  • A Retrospective of Cobalt-60 Radiation Therapy: “The Atom Bomb That Saves Lives”
    MEDICAL PHYSICS INTERNATIONAL Journal, Special Issue, History of Medical Physics 4, 2020 A RETROSPECTIVE OF COBALT-60 RADIATION THERAPY: “THE ATOM BOMB THAT SAVES LIVES” J. Van Dyk1, J. J. Battista1, and P.R. Almond2 1 Departments of Medical Biophysics and Oncology, Western University, London, Ontario, Canada 2 University of Texas, MD Anderson Cancer Center, Houston, Texas, United States Abstract — The first cancer patients irradiated with CONTENTS cobalt-60 gamma rays using external beam I. INTRODUCTION radiotherapy occurred in 1951. The development of II. BRIEF HISTORY OF RADIOTHERAPY cobalt-60 machines represented a momentous III. LIMITATIONS OF RADIATION THERAPY breakthrough providing improved tumour control UNTIL THE 1950s and reduced complications, along with much lower skin reactions, at a relatively low cost. This article IV. RADIOACTIVE SOURCE DEVELOPMENT provides a review of the historic context in which the V. THE RACE TO FIRST CANCER TREATMENTS advances in radiation therapy with megavoltage VI. COBALT TRUTHS AND CONSEQUENCES gamma rays occurred and describes some of the VII. COBALT TELETHERAPY MACHINE DESIGNS physics and engineering details of the associated VIII. GROWTH AND DECLINE OF COBALT-60 developments as well as some of the key locations and TELETHERAPY people involved in these events. It is estimated that IX. COBALT VERSUS LINAC: COMPETING over 50 million patients have benefited from cobalt-60 teletherapy. While the early growth in the use of MODALITIES cobalt-60 was remarkable, linear accelerators (linacs) X. OTHER USES OF COBALT-60 provided strong competition such that in the mid- XI. SUMMARY AND CONCLUSIONS 1980s, the number of linacs superseded the number of ACKNOWLEDGEMENTS cobalt machines.
    [Show full text]
  • STI/PUB/1153 Vol. 2
    STANDARDS AND CODES OF PRACTICE IN MEDICAL RADIATION DOSIMETRY VOLUME 2 ALL BLANK PAGES HAVE BEEN RETAINED INTENTIONALLY IN THIS WEB VERSION. BLANK PROCEEDINGS SERIES STANDARDS AND CODES OF PRACTICE IN MEDICAL RADIATION DOSIMETRY PROCEEDINGS OF AN INTERNATIONAL SYMPOSIUM HELD IN VIENNA, AUSTRIA, 25–28 NOVEMBER 2002, ORGANIZED BY THE INTERNATIONAL ATOMIC ENERGY AGENCY, CO-SPONSORED BY THE EUROPEAN COMMISSION (DIRECTORATE-GENERAL ENVIRONMENT), THE EUROPEAN SOCIETY FOR THERAPEUTIC RADIOLOGY AND ONCOLOGY, THE INTERNATIONAL ORGANIZATION FOR MEDICAL PHYSICS AND THE PAN AMERICAN HEALTH ORGANIZATION, AND IN CO-OPERATION WITH THE AMERICAN ASSOCIATION OF PHYSICISTS IN MEDICINE, THE EUROPEAN FEDERATION OF ORGANISATIONS FOR MEDICAL PHYSICS, THE INTERNATIONAL COMMISSION ON RADIATION UNITS AND MEASUREMENTS, THE INTERNATIONAL SOCIETY FOR RADIATION ONCOLOGY AND THE WORLD HEALTH ORGANIZATION In two volumes VOLUME 2 INTERNATIONAL ATOMIC ENERGY AGENCY VIENNA, 2003 Permission to reproduce or translate the information contained in this publication may be obtained by writing to the International Atomic Energy Agency,Wagramer Strasse 5, P.O. Box 100,A-1400 Vienna,Austria. © IAEA, 2003 IAEA Library Cataloguing in Publication Data International Symposium on Standards and Codes of Practice in Medical Radiation Dosimetry (2002 : Vienna, Austria) Standards and codes of practice in medical radiation dosimetry : proceedings of an international symposium held in Vienna, Austria, 25–28 November 2002 / organized by the International Atomic Energy Agency ; co-sponsored by the European Commission, Directorate- General Environment...[et al.]. In 2 vols. — Vienna: The Agency, 2003. 2 v. ; 24 cm. — (Proceedings series, ISSN 0074–1884) Contents : v. 2. STI/PUB/1153 ISBN 92–0–111403–6 Includes bibliographical references. 1.
    [Show full text]
  • Intercomparison Procedures in the Dosmetry of And
    INTERCOMPARISON PROCEDURES DOSMETRE TH N I F YO HIGH-ENERGY X-RAY AND ELECTRON BEAMS REPOR ADVISORN A F TO Y GROUP MEETING ORGANIZED BY THE INTERNATIONAL ATOMIC ENERGY AGENCY AND HELD IN VIENNA 2-6 APRIL 1979 A TECHNICAL DOCUMENT ISSUEE TH Y DB INTERNATIONAL ATOMIC ENERGY AGENCY, VIENNA, 1981 The IAEA does not maintain stocks of reports in this series. However, microfiche copies of these reports can be obtained from IN IS Microfiche Clearinghouse International Atomic Energy Agency Wagramerstrasse5 0 10 P.Ox Bo . A-1400 Vienna, Austria on prepayment of Austrian Schillings 25.50 or against one IAEA microfiche service coupon to the value of US S2.00. CONTENTS REPORT AND RECOMMENDATIONS OF THE ADVISORY GROUP Repor recommendationd an t Advisore th f so y Group..................7 . APPENDI . I XIAEA/WH O postal dose intercomparison (TLD) for high energy X-ray therapy. Instruction sheet................7 1 . APPENDI . XII IAEA/WH O postal dose intercomparison (TLD) for high energy X-ray therapy. Data sheet........................ 21 EXPERIENCE WITH AND THE NEED FOR DOSE INTERCOMPARISONS The IAEA/WHO thermoluminescent dosimetry intercomparison used for the improvemen clinicaf o t l dosimetry ............................7 2 . N.T. Racoveanu A surve f clinicallo y y applied dosimetry (Summary e reporth n o t IAEA/WHO postal dose intercomparison of cobalt-60 telecurie units with TLD) ........................................................3 3 . Seelenta. W g Dose intercomparison programm Regionae th f o e l Reference Centre of Argentina ...................................................... 45 R. Gonzalez, M.S. de Fernandez Gianotti Experience in intercomparison at an SSDL for orthovoltage and high energy beams ................................................. 51 G.
    [Show full text]
  • Chapter 5. Treatment Machines for External Beam Radiotherapy
    Review of Radiation Oncology Physics: A Handbook for Teachers and Students CHAPTER 5. TREATMENT MACHINES FOR EXTERNAL BEAM RADIOTHERAPY ERVIN B. PODGORSAK Department of Medical Physics McGill University Health Centre Montréal, Québec, Canada 5.1. INTRODUCTION Since the inception of radiotherapy soon after the discovery of x-rays by Roentgen in 1895, the technology of x-ray production has first been aimed toward ever higher photon and electron beam energies and intensities, and more recently toward computerization and intensity-modulated beam delivery. During the first 50 years of radiotherapy, the techno- logical progress has been relatively slow and mainly based on x-ray tubes, Van de Graaff generators and betatrons. The invention of the cobalt-60 teletherapy unit by H.E. Johns in Canada in the early 1950s provided a tremendous boost in the quest for higher photon energies, and placed the cobalt unit into the forefront of radiotherapy for a number of years. The concurrently developed medical linear accelerators (linacs), however, soon eclipsed the cobalt unit, moved through five increasingly sophisticated generations, and became the most widely used radiation source in modern radiotherapy. With its compact and efficient design, the linac offers excellent versatility for use in radiotherapy through isocentric mounting and provides either electron or megavoltage x-ray therapy with a wide range of energies. In addition to linacs, electron and x-ray radiotherapy is also carried out with other types of accelerators, such as betatrons and microtrons. More exotic particles, such as protons, neutrons, heavy ions, and negative π mesons, all produced by special accelerators, are also sometimes used for radiotherapy; however, most of the contemporary radiotherapy is carried out with linacs or teletherapy cobalt units.
    [Show full text]
  • Book of Extended Synopses
    International Symposium on Standards, Applications and Quality Assurance in Medical Radiation Dosimetry (IDOS 2019) 18–21 June 2019 Vienna, Austria Book of Extended Synopses Organized by the CN-273 TABLE OF CONTENTS ORAL PRESENTATIONS Small Field Dosimetry Implementation of the International Code of Practice on Dosimetry of Small Static Fields used in External Beam Radiotherapy (TRS-483) ........................................................... 11 Detector Choice for Depth Dose Curves Including the Build-Up Region of Small MV Photon Fields .................................................................................................................. 15 Output Correction Factors for Eight Ionization Chambers in Small Static Photon Fields ........................................................................................................................................ 17 Reference Dosimetry of a New Biology-Guided Radiotherapy (BgRT) System Following the IAEA TRS-483 CoP ................................................................................................. 20 Uncertainty Contributors in the Dosimetry of Small Static Fields................................. 23 Small Field Photon Beams Audit Pilot Study: Preliminary Results .............................. 25 On the Implementation of the Plan Class-Specific Reference Field Concept Using Multidimensional Clustering of Plan Features ............................................................... 27 Computational Dosimetry Determination of Wair in High-Energy Clinical Electron
    [Show full text]
  • Radiation Therapy Coding
    Ed 21:01 Radiation March 2021 Missouri Cancer Registry and Research Center Therapy 2021 Show-Me-Tips Coding...Abstracting...Education… Radiation Therapy Coding Radiation Delivery Systems/Approaches and Coding LINEAR ACCELERATOR - Linac If the radiation treatment summary refers to beam energies, such as: • 6X or 6MV, 10X or 10MV • 12X or 12MV, 15X or 15MV Then the treatment modality will always be 02, external beam, photons (a Linac was used to deliver the EBRT treatment) If radiation treatment summary refers to treatment delivery as: • E, eboost, MeV or “en face” Code the treatment modality 04, external beam, electrons (a Linac can also deliver electron therapy) IORT Delivery Technology & Coding IORT FOR BREAST CANCER, Volume: 41 - Partial Breast. Lymph Nodes are not Targeted! Equipment RT Delivery Modality Planning Comments Method Technique Zeiss Intrabeam 50 kVp Linac 02-Photons 02: Low energy x-ray/ Isotope-free. No photon therapy radioactive source used XOFT Axxent 50 kVp Linac 02-Photons 02: Low energy x-ray/ Isotope-free. No photon therapy radioactive source used LIAC 10/12 by Electron 04-Electrons In most cases, Max energy: 10 MeV, Sordina IORT accelerator 04-3D conformal 12 MeV NOVAC by Electron 04-Electrons In most cases, Check with Rad Onc for Sordina IORT accelerator 04-3D conformal planning technique Mobetron Electron 04-Electrons In most cases, Energies: 6, 9, 12 MeV accelerator 04-3D conformal Strut Assisted Ir-192 Sources 09-Brachy, 88 - NA Accelerated partial breast Volume (HDR) Intracavitary HDR irradiation (PBI) Implant
    [Show full text]
  • An Overview of Auger-Electron Radionuclide Therapy
    Current Drug Discovery Technologies, 2010, 7, 000-000 1 Targeting the Nucleus: An Overview of Auger-Electron Radionuclide Therapy Bart Cornelissen* and Katherine A Vallis MRC/CRUK Gray Institute for Radiation Oncology and Biology, University of Oxford, Oxford, United Kingdom Abstract: The review presented here lays out the present state of the art in the field of radionuclide therapies specifically targeted against the nucleus of cancer cells, focussing on the use of Auger-electron-emitters. Nuclear localisation of radi- onuclides increases DNA damage and cell kill, and, in the case of Auger-electron therapy, is deemed necessary for thera- peutic effect. Several strategies will be discussed to direct radionuclides to the nucleoplasm, even to specific protein tar- gets within the nucleus. An overview is given of the applications of Auger-electron-emitting radionuclide therapy target- ing the nucleus. Finally, a few suggestions are made as how radioimmunotherapy with nuclear targets can be improved, and the challenges that might be met, such as how to perform accurate dosimetry measurements, are examined. Keywords: Auger-electron, radionuclide, radioimmunotherapy, nucleus, targeted radiotherapy, molecular radiotherapy, PRRT. 1. INTRODUCTION tumour from within. Because of tumour-specific delivery, radionuclide therapy is also called targeted or molecular ra- The management of solid cancers relies on a combination diotherapy (tRT). Where antibodies or peptides are used to of surgery, systemic chemotherapy and locally delivered guide the radionuclide to epitopes or receptors on malignant radiotherapy. External beam X-ray radiotherapy (XRT) is cells, the terms radioimmunotherapy (RIT) or peptide recep- used in approximately 50% of all cancer patients as it is able tor radionuclide therapy (PRRT) are used, respectively.
    [Show full text]
  • 2020 VERSION 4 FINAL Practice Guideline Radiotherapy Skin Care Llv1
    SCoTHE SOCIETY & COLLEGER OF RADIOGRAPHERS The Society and College of Radiographers Practice Guideline Document Radiation Dermatitis Guidelines for Radiotherapy Healthcare Professionals Second revised edition April 2020 Review date: 2025 ISBN: 978-1-909802-49-0 Endorsed by © The Society and College of Radiographers 2020. Material may only be reproduced from this publication with clear acknowledgement that it is the original source. If text is being translated into another language or languages, please include a reference/link to the original English-language text. Contents Page Executive summary 1 1. Introduction 4 2. Scope and purpose 8 3. Guideline question 8 4. Guideline development process 8 5. Guideline methodology 9 6. Radiotherapy skin care 26 7. Guideline recommendations 28 8. Implementation strategies 32 9. Recommendations for future research 33 10. Date of publication, review and updating 34 11. References 35 12. List of appendices (separate documents) Appendix 1 Group members Appendix 2 Stakeholder consultation combined and outcomes Appendix 3 External stakeholder comment form Appendix 4 2014 Systematic review 2014 Appendix 5 2014 On-going trails table (1) Appendix 6 2014 On-going trials table (2) Appendix 7 2019 Summary of evidence table Appendix 8 2019 Review summary of evidence table Appendix 9 Other interventions Appendix 10 Staff infosheet skin care Appendix 11 Staff infosheet skin care A5 leaflet Appendix 11 Staff infosheet skin care A5 leaflet – PRINT READY Appendix 12 Patient information sheet Appendix 13 Patient infosheet skin care A5 leaflet Appendix 13 Patient infosheet skin care A5 leaflet – PRINT READY Appendix 14 Skin care presentation Oncology Nursing Society (UKONS) colleagues have been involved in the writing of this document and UKONS recognises it as expert guidelines.
    [Show full text]
  • Aapm Report No
    AAPM REPORT NO. 249 (Revision of AAPM Report No. 90) Essentials and Guidelines for Clinical Medical Physics Residency Training Programs Report from the Work Group on Periodic Review of Medical Physics Residency Training October 2013 DISCLAIMER: This publication is based on sources and information believed to be reliable, but the AAPM and the editors disclaim any warranty or liability based on or relating to the contents of this publication. The AAPM does not endorse any products, manufacturers, or suppliers. Nothing in this publication should be interpreted as implying such endorsement. © 2013 by American Association of Physicists in Medicine DISCLAIMER: This publication is based on sources and information believed to be reliable, but the AAPM, the editors, and the publisher disclaim any warranty or liability based on or relating to the contents of this publication. The AAPM does not endorse any products, manufacturers, or suppliers. Nothing in this publication should be interpreted as implying such endorsement. ISBN-13: 978-1-936366-25-5 © 2013 by American Association of Physicists in Medicine All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means (electronic, mechanical, photocopying, recording, or otherwise) without the prior written permission of the publisher. Published by American Association of Physicists in Medicine One Physics Ellipse College Park, MD 20740-3846 ESSENTIALS AND GUIDELINES FOR CLINICAL MEDICAL PHYSICS RESIDENCY TRAINING PROGRAMS Report from the Work Group on Periodic Review of Medical Physics Residency Training Members: Joann I. Prisciandaro, Ph.D. (Work Group Chair) University of Michigan, Ann Arbor, Michigan Charles E.
    [Show full text]
  • Commercial Radioactive Sources
    Commercial Radioactive CNS Sources: Surveying the OCCASIONAL PAPER #11 JANUARY 2003 Security Risks Charles D. Ferguson, Tahseen Kazi, Judith Perera THE CENTER FOR NONPROLIFERATION STUDIES The mission of the Center for Nonproliferation Studies (CNS) is to combat the spread of weapons of mass destruction by training the next generation of nonproliferation specialists and disseminating timely information and analysis. Dr. William C. Potter is the director of CNS, which has a staff of more than 60 full-time personnel and approximately 75 student research assistants, with offices in Monterey, CA; Washington, DC; and Almaty, Kazakhstan. CNS is the largest nongovernmental organization in the United States devoted exclusively to research and training on nonproliferation issues. CNS gratefully acknowledges the support of the following funders and thanks them for their commitment to our mission: the Carnegie Corporation of New York, the Center for Global Partnership, the Compton Foundation, the Ford Foundation, the Japan-United States Friendship Commission, the John D. and Catherine T. MacArthur Foundation, the Nuclear Threat Initiative, the Ploughshares Fund, the Prospect Hill Foundation, and the Scherman Foundation. For more information on the projects and publications of CNS, contact: Center for Nonproliferation Studies Monterey Institute of International Studies 460 Pierce Street Monterey, California 93940 USA Tel: 831.647.4154 Fax: 831.647.3519 E-mail: [email protected] Website: http://cns.miis.edu CNS Publications Staff Editor-in-Chief Editor Copy Editor Leonard S. Spector Scott Parrish Bill Gibson Managing Editor Cover Design Lisa Donohoe Cutting Edge Design, Washington, DC Cover photos: Background photo: Radioactive sources that were used in mobile irradiators in the former Soviet Union and that contain 3,500 curies of cesium-137; photo credit: IAEA.
    [Show full text]
  • Radiation Oncology: a Century of Achievements
    PERSPECTIVES genotoxic stress. Genes Dev. 14, 2989–3002 Competing interests statement were four main schools of radiation oncology (2000). The authors declare no competing financial interests. 145. Gatei, M. et al. Ataxia telangiectasia mutated (ATM) in the twentieth century (BOX 1):the German kinase and ATM and Rad3 related kinase mediate school (1900 to ~1920), the French school phosphorylation of Brca1 at distinct and overlapping Online links sites. In vivo assessment using phospho-specific (1920 to ~1940), the British school (1940 to antibodies. J. Biol. Chem. 276, 17276–17280 DATABASES ~1960) and the United States then European (2001). The following terms in this article are linked online to: 146. Deng, C. X. & Brodie, S. G. Roles of BRCA1 and its Cancer.gov: http://cancer.gov/ Union school (1970 to date). interacting proteins. Bioessays 22, 728–737 breast cancer | lung cancer The discovery of X-rays, in 1895, by 2000). Entrez Gene: 147. Scully, R. & Livingston, D. M. In search of the tumour- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene Wilhelm Conrad Röntgen in Germany (FIG. 1) suppressor functions of BRCA1 and BRCA2. Nature BCL2 | BCL-XL | CDKN1A | CSA | CSB | Csb | cyclin B1 | DDB2 | and of natural radioactivity a few months 408, 429–432 (2000). Ku86 |lamin A/C | MDM2 | MLH1 | MSH2 | NUP160 | p53 | TAP | UBF | VHL | Xpa | Xpc | XPC later, by the French physicist Henry Becquerel, Acknowledgements were two such breakthroughs that paved the We would like to thank The National Institute of Health, The FURTHER INFORMATION Swedish Cancer Foundation, Cancer Research UK and the Mats Ljungmans’ lab: way for a new era in science.
    [Show full text]